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Abstract. In dogs, melanoma is a highly aggressive tumor, diagnosis and prognosis are still based on 
histological signs of malignancy. The purposes of the present study were to evaluate the sensitivity and 
specificity of several melanocytic markers, and, to investigate the relation between tumor growth fraction 
and classical histological signs of malignancy. Twenty-two dog melanoma samples (16 cutaneous tumors 
and 6 oral) were selected, and ten non melanocytic tumors were the negative control. Tumor histological 
malignancy criteria were compared with the growth phase, which was expressed by Ki67 immunolabeling 
and measured by quantitative computerized analysis. Of the 22 tumors, 16 were positive to Melan A, 20 to 
Vimentin and all of them to S100. When refer to specificity, Melan A did not stain the negative control 
samples, Vimentin stains seven, and S100 all of them. The most melanocytic neoplasms, regardless of the 
location, shown clear signs of malignancy, they were anaplastic, invasive tumors, with high mitotic index, 
and extended necrosis. Growth phase index was also very high, but it was not correlated with any of the 
histological features of malignancy, and neither to histological type. The only positive correlation was 
those between mitotic index and the extension of necrotic areas (r=0.5, p<0.05). These findings 
recommend Melan A because of its very high specificity. However, it has relatively low sensitivity, 
especially in amelanotic tumors. The present study did not find any correlation between growth phase and 
classic histological features of malignancy.   
 
Keywords: melanoma, dog, Melan A, Vimentin, S100, growth phase index, malignancy criteria 
 
INTRODUCTION 
 
Melanoma is a very aggressive tumor, the chances of recovery are generally poor, and 
they relay on early diagnosis. The diagnosis of melanoma may be difficult even for experienced 
pathologists, particularly in tumors without significant amount of melanin. In addition, canine 
melanocytic neoplasms have a wide variety of histologic morphology that makes them difficult to 
distinguish from other tumor types like tumors of the hematopoietic system, sarcomas and 
carcinomas (Smith et al., 2002). Immunohistochemistry is widely used to confirm the diagnosis 
of melanoma; there are many melanoma markers with variable sensitivity and specificity. 
Commonly used melanocytic markers are Melan A, S100 and Vimentin (Smendly et al., 2011).   
Melan A (melanocyte antigen), known as MART-1 (Melanoma Antigen Recognized by T 
cells), is a cytoplasmic protein. Its function is still not elucidated yet, but Melan A is involved in 
tumor recognition by Tc lymphocytes. It is a highly specific protein, but its sensitivity is lower than 
other markers (92 to 57.66%) (Ramos-Vara et al., 2000, Cangul et al., 2001, Smendly et al., 2011).   
S100 represents a low molecular weight protein family located both intra cytoplasmic 
and in nucleus, found in neural crest derived cells, but also in chondrocytes, adipocytes, 
myoepithelial cells, macrophages, dendritic cells, keratinocytes etc. S100 proteins have multiple 
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cell functions, as phosphorylation regulators, transcription factors etc. They are highly sensitive 
(80 to 98%) () but have poor specificity. S100 label also schwannomas, histiocytomas, and 
several sarcomas. (Ramos-Vara et al., 2000, Smendly et al., 2011).  
Vimentin is a intra cytoplasmic protein involved in stability of cell organelles, fount in 
almost all melanomas (85-100%), but also in other tumors as sarcomas. Therefore, despite its 
high sensibility, vimentin has a low specificity (Ramos-Vara et al., 2000, Cangul et al., 2001, 
Smendly et al., 2011). Growth fraction, assessed by immunohistochemical labeling for Ki67, is 
evaluated as prognostic factor in several studies, including canine melanomas (Smendley et al., 
2011). Ki67 is a nonhistone nuclear protein expressed in all phases of the cell cycle, but not in 
resting cells (G0) (Bullwinkel et al., 2006). Although each study use a different method to 
measure and rapport the Ki67 index, all they all show significant difference between benign and 
malignant melanocytic neoplasms. It is correlated with median survival and mitotic counts (Roels 
et al., 1999), Ki67 seams to be an important statistical prognostic marker for melanocytic 
neoplasms (Bergin et al., 2011).  
The first aim of the present study was to compare the immunoreactivity of Melan A, 
Vimentin and S100 in melanomas and to determine their cross reactivity with cutaneous non-
melanocytic tumors. The second objective was to investigate the relation of tumor growth fraction 
(Ki 67 positive cells) to cell type, mitotic index, necrosis and tumor infiltrating lymphocytes. 
 
MATERIALS AND METHODS 
 
The archive of the Pathology Department were searched for canine melanocytic 
neoplasms removed surgically. The selection criteria were not only the diagnosis, but also the 
presence of enough tissue for immunohistochemical procedures. 27 melanoma cases and 5 other 
cutaneous tumors were selected, and histological sections of each case was examined by two, 
experienced pathologists (C.C. and M.T) to confirm the diagnosis. The melanoma diagnosis was 
confirmed for 22 cases, other were non melanocytic tumors.  
The tumors were classified according to cell type (dendritic, balloon, 
epithelioid/polygonal, spindle, mixed), melanin content (0 = amelanotic melanoma, 1= week 
melanotic melanoma, 2 - high melanotic melanoma), mitotic index (number of mitoses /10 high 
power fields - HPF), and necrosis (0- no necrotic areas, 1- reduced necrotic areas, 2- extended), 
tumor infiltrating lymphocytes inside the tumor 0/1/2).  
The samples in study were all malignant tumors, mainly cutaneous melanomas (n= 16) 
and secondly tumors raised in mouth cavity (n= 6). The cutaneous tumors were from different 
skin areas no toe or ungual melanomas were found. Mouth tumors originated in various regions 
like gingival, lip (mucocutaneous junction) and palatum.  
As negative control for melanocytic markers, normal tissue and ten non melanic tumors 
including fibrosarcomas (3), carcinomas (4), fibropapilomas (2), and one perianal gland adenoma 
were also evaluated. For Ki67 immunolabeling the positive control included canine limph nodes 
while internal positive controls consisted of nuclear labeling of keratinocytes within the section.  
After dewaxing of sections, rehydrated slides were steamed in target retrieval solution 
(Tris EDTA buffer [pH 9]) for 20 minutes and then cooled in this solution for an additional 20 
minutes. The melanin bleach was performed by overnight exposure to H2O2 3% in PBS BSA 1% 
(Roels et al., 1999). This method was able to remove the most of melanin, without interfering 
with immunohistochemistry (data not shown). It provides also the blocking of endogenous 
peroxidase. Bleaching was a standard step even for amelanotic melanomas to avoid any 
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difference among the tumors in study. Serum-free protein block solution (Dako) was than applied 
to reduce nonspecific background staining. Three melanocytic markers were used mouse 
monoclonal antibody anti-Melan A. clone 103 (Dako, Glostrup, Denmark) (1:50), polyclonal 
rabbit anti-S100 antibody (Dako) (1:200) and monoclonal mouse anti-Vimentin antibody clone 
Vim 3B4. The growth fraction was evaluated with monoclonal mouse antihuman Ki67 antigen 
clone MIB-1 (Dako) (1:100). For negative control the primary antibody was replaced with mouse 
IgG1 Negative Control (Dako) (1:50). All antibodies were subject of the same protocol, 
established after a laborious study (data not shown), to avoid day-to-day variation all samples and 
all markers were labeled simultaneously. Primary antibodies were incubated overnight at 4°C.  
An avidin biotin HRP diaminobenzidine (DAB) detection method (Universal LSAB kit, 
Dako) was used according to manufacturer specifications. Azure B 1% (Sigma) staining was 
done in all cases, following hematoxylin (Dako) contrastaining. Even small amounts of melanin 
are difficult to distinguish from DAB precipitate, Azure B stained the melanin green and DAB 
remained brown.  Immunoreactivity for melanocytic markers was semiquantitavelly evaluated by 
two observers without knowledge of the case (I.M and B.S.), and express in a 4-grade scale (0= 
no positive cells, 1 = <10% positive cells, 2 = 11-50% positive cells, 3 = >50% positive cells) 
(adapted from Ramos-Vara and Miler, 2011). The sensitivity of the three melanocytic markers to 
detect the dog melanotic tumors was determined based on the antibody’s ability to label the 22 
selected cases. The specificity of each antibody to diagnose these neoplasms was determined 
based on the absence of labeling of 10 subcutaneous non-melanocytic tumors also included in 
study (negative controls).  
Evaluation of the Ki67, was done, by one observer I.B. without knowledge of the case, 
according to method described by Bergin et al., (2011), modified for computer image analysis. 
The tumors were scanned at low magnification for areas of highest ki67 labeling. Areas of 
necrosis or inflammation were avoided, because inflammatory cells can be positive to Ki67. Five 
400x fields within the areas of heaviest ki67 labeling were photographed. Each photo was 
transferred to a computer and processed in Quick Photo Micro 2.3. software. For an easy 
counting, to each image was applied a gridline of 0.05mm2 at a magnification of 400x. Afterward, 
the counting of positive nuclei to ki67 was made with “object” tool. Immunolabeling was 
expressed as the mean number of positive cells. 
Statistical analysis – All data are reported as the mean ± SEM. To assume Gaussian 
distribution normality distribution was checked by Shapiro-Wilk normally test. Pearson test 
analyzed the correlation between normally distributed values (proliferation phase index -Ki67+ 
cells/400 x field, and mitotic index). For the values, which were not normally distributed 
(necrosis intensity, tumor infiltrating lymphocytes, melanin content, and the percentage of tumor 
cells positive to melanocytic markers), multiple pare-wise comparison was performed by one-
way analysis of variance Kruskal-Walis, followed by post test Dunns. Spearman’s correlation 
was the test of choice, in order to asses the correlation between non normally distributed 
variables. Statistical significance was at p<0.05 (95% confidence interval).  
Statistical values and figures were obtained using GraphPad Prism 5.0 software. 
 
RESULTS AND DISCUSSION 
 
The melanocytic tumors were classified by the prevalent cell type in five categories 
dendritic, balloon cells, epithelioid/polygonal, spindle cell and mixed (Ramos-Vara and Miler, 2011). 
Further, the tumor samples were organized according to melanin content, and location (Tab.1).  The 
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clinical and histological features of the most melanomas were intensively detailed in a previous study 
(Taulescu et al., 2009). All melanocytic tumors were diagnosed as malignant, invasive, Clark’s level 
4, one tumor had level 5. However, the malignancy degree showed some variation among the 
melanomas in study, necrosis intensity was variable as well as nuclear variability and pagetoid 
infiltration of the epidermal region by individual cells and nest of tumors cells.  
All tree melanocytic antigens were located in cytoplasm. Immunoreactivity was strong 
(3+) in 3, 12, and 20 samples for Melan A, Vimentin and S100 respectively.  
All Melan A negative samples were positive for Vimentin and S100, and all melanoma 
samples were positive for at least two melanocytic antigens. Of 12 melanotic melanomas 10 
(83%), 69 (78.4%) were positive for Melan A, and Vimentin; of 10 amelanotic melanomas 6 
(60%), 10 (100%) and 10 (100%) were positive for Melan A, Vimentin and S100 respectively. 
The percentage of Melan A positive cells seems to be higher in melanotic melanomas, 
according to the intensity of melanin content (fig 1.), but no significant correlation was found (r= 
-0.142, p>0.05). The immunolabeling did not show significant difference between cutaneous 
melanomas and those raised in oral cavity (Tab 1).  
When immunohistochemical results were grouped according to phenotype (Tab. 1.), 
mixed and spindle cell variants were the least likely to label Melan A (90%, and 75% 
respectively), while the lowest percentage was found in epitelioid melanomas (50%).  
However, no statistical significant difference in percentage of Melan A positive cells 
was found among different melanomas cell types (fig. 2.).  
 
Tab. 1.  
 
Immunohistochemical results according to phenotype, melanin content and location 
(Number of positive tumors/percentage) 
 
Type n Melan A Vimentin  S100 
Dendritic 1 1 (100%) 1 (100%) 1 (100%) 
Balloon  1 0 (0%) 1 (100%) 1 (100%) 
Epithelioid/polygonal  6 3 (50%) 4 (66%) 6 (100%) 
Spindle 4 3 (75%) 4 (100%) 4 (100%) 
Mixed 10 9 (90%) 10 (100%) 10 (100%) 
Melanotic melanomas 12 10 (83%) 10 (83%) 12 (100%) 
Amelanotic melanomas 10 6 (60%) 10 (100%) 10 (100%) 
Cutaneous melanomas 16 12 (75%) 16 (100%) 16 (100%) 
Oral melanomas 6 4 (66%) 4 (66%) 6 (100%) 
Total 22 16 (72%) 20 (90%) 22 (100%) 
 
None of the 10 negative control cases (non melanocytic cutaneous neoplasms) were positive for Melan A. Seven 
neoplasms (fibrosarcomas, fibropapilomas, and the perianal gland tumors) were positive for Vimentin, while 3 
carcinomas of sebaceous gland were negative. S 100 labeled all ten samples (Tab. 2). 
 
 
The sensitivity and specificity of melanocytic markers in study showed a wide variation, 
Melan A (16 of 22 72% sensitivity) was highly specific (100%).  
In contrast, the other two markers Vimentin and S100 were more sensitive (90% and 
100% respectively), but highly unspecific (40% and 10%) (Tab. 3).  
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Tab. 2.  
 
Immunohistochemical results in non-melanocytic cutaneous tumors 
(Number of positive tumors/percentage) 
 
Type n M
elan A 
Vi
mentin  
S 
100 
fibrosarcoma 3 0 3 3 
carcinoma (sebaceous gland) 3 0 0 3 
fibropapilomas 2 0 2 2 
perianal gland adenoma 1 0 1 1 
perianal gland carcinoma 1 0 1 1 
Total 1
0 
0 7 10 
 
 
Tab. 3. 
  
Sensitivities and specificities of Melan A, Vimentin and S100, for detection of canine melanocytic 
tumors (percentage of positive tumors) 
Antibody Sensitivity (%) Specificity (%) 
Melan A 72% 100% 
Vimentin 90% 40% 
S100 100% 10% 
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Fig. 1. Correlation between melanin content and Melan A immunolabeling and melanin content 
(mean ± SEM). (0= no positive cells, 1 = <10% positive cells, 2 = 11-50% positive cells, 3 = >50% positive 
cells melanin content; 0 = amelanotic melanoma, 1= week melanotic melanoma, 2 - high melanotic melanoma) (r= -
0.142, p>0.05) 
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Fig. 2. Correlation between Melan A immunolabeling and cel type. 
(0= no positive cells, 1 = <10% positive cells, 2 = 11-50% positive cells, 3 = >50%  
positive cells melanin content) 
 
Melan A is a widely used differentiation marker for melanocytic tumors (Ramos-Vara et 
al., 2000). In the present study, Melan A was 100% specific, but not very sensitive marker, its 
sensitivity was 72% (the most of the cases shown 10% to 50% of positive cells); our data were 
close to previous studies (Smendley et al., 2011, Ramos-Vara et al., 2011). Its immunoreactivity 
was higher in mixed and spindle melanomas and lower in ephitelioid ones. Other studies find 
relatively similar Melan A expression among the different tumor types (Ramos-Vara et al., 
2011). Melan A reactivity for melanotic tumors (83%) was higher than that for amelanotic 
melanomas (60%), similar to other studies (Cangul et al., 2001, Ramos-Vara et al., 2011).  
However, the percentages of Melan A positive cells within the tumor tissue were not 
correlated with melanin content (fig. 1.), or other histological malignancy criteria. The 
significance of melanin content as predictive marker is controversial.  
While some authors consider the melanin content irrelevant (Smith et al., 2002), recent 
studies suggest that dogs with heavily pigmented tumors had significantly higher rate of survival 
than dogs with amelanotic or low pigmented, but dogs with moderate pigment were not clearly 
differentiated by other categories (Berghin et al., 2011). 
Vimentin and S100 were found highly sensitive but less specific for the detection of 
melanocytic neoplasms. S100 labeled all cutaneous tumors used as negative control, while 
Vimentin let unstained the carcinomas only. All melanomas negative to Melan A were positive to 
Vimentin, so the absence of Melan A and Vimentin excludes the diagnosis of melanoma, but the 
presence of Vimentin staining in absence of Melan A does not confirm the melanoma diagnosis.  
From our point of view, Melan A was a reliable marker to confirm the diagnosis of 
melanocytic tumor, but it was far from being perfect because of its relatively low sensitivity. 
Vimentin might be also useful to provide a clue for Melan A negative tumors, but it is rather 
excluding the melanoma diagnosis than confirming it. The diagnosis of melanocytic tumor, in 
Melan A negative samples, most of them amelanotic, remained a challenge.  
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The histological malignancy parameters of the tumors are presented in Table 4. In some 
tumors, the histological aspects varied from one area to another, in such cases the diagnose was 
based on the most malignant part of the tumor. 10 of 22 tumors had an inflammatory component 
within the tumor tissue consisting mainly in lymphocytes, the lymphocytes surrounding tumor 
were not counted, because they are considered to non significant for the tumor outcome (Smith et 
al., 2002). Necrosis was also found in the most of the samples in study; only four of them showed 
no necrosis, the necrotic areas were invaded by neutrophilic infiltrate.  
Mitotic index was very high in almost all melanomas in study, only one sample showed 
values lower than the limit of 4 mitotic figures / 10 HPF (Smith et al., 2002, Schultheiss, 2006, 
Smendly et al.,  2012). The growth fraction (Ki67+cells /HPF) varied from 42 to 179.2, the 
positive Ki67 nuclei were scattered within the tumor tissue. In all samples the Ki67+ cell 
concentration was over the threshold of 19.5 established by Smedly et al., (2011). No significant 
difference between oral and cutaneous location, or among different tumor types was found.  
 
 
Tab. 4.  
 
Malignancy parameters evaluated for 22 canine melanomas 
 
No. Diagnosis Cell type Mitotic index  
(no.mitoses/10 HPF) 
Necrosis
0/1/2 
TIL  
0/1/2 
Growth fraction 
(Ki67+cells/HPF) 
1 CM Dendritic 40 1 2 145 
2 CM Mixt 12 1 0 147.4 
3 CM Baloon type  43 2 2 42 
4 CM Spindle 11 1 2 65.4 
5 CM Mixt 13 2 0 58.2 
6 OM Mixt 23 2 2 72.1 
7 CM Mixt 35 1 0 67.5 
8 CM Mixt 55 2 2 168 
9 CM Epithelioid 15 1 1 53.7 
10 OM Epithelioid 24 2 0 41.2 
11 CM Spindle 2 0 0 97.8 
12 CM Spindle 21 0 0 149.4 
13 OM Epitelioid 53 2 0 125.3 
14 OM Epitelioid 25 2 0 88.4 
15 CM Mixt 22 0 0 14.4 
16 OM Epithelioid 64 2 1 57.2 
17 OM Epithelioid 32 2 0 76.3 
18 CM Mixt 26 1 0 80 
19 CM Mixt 22 0 0 62.5 
20 CM Mixt 81 2 1 128.4 
21 CM Mixt 32 1 1 91.8 
22 CM Spindle  41 2 1 179.2 
CM (Cutaneous Melanoma), OM (Oral Melanoma), TIL (Tumor Infiltrating Lymphocytes) 
 
 
Mitotic index was significantly correlated with the necrosis intensity (r=0.5, p<0.05) 
(fig. 3), but no correlations were found between the growth fraction and the mitotic index or 
tumor infiltrating lymphocytes.   
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Fig. 3. Correlation between necrosis and mitotic index mitotic index (number of mitoses/400x 
field), necrosis (0- no necrotic areas, 1- reduced necrotic areas, 2- extended) (r=0.5, p<0.05) 
 
Malignancy criteria in dog melanoma is still highly controversial issue, the melanocytic 
tumors showed a high variation in malignancy criteria ranging from strictly benign to highly 
malignant. However, the classic categories accepted in veterinary pathology for the animal 
melanocytic tumors are melanocytoma and melanoma (Goldschmidt et al., 1998). The borderline 
categories described in human pathology are not accepted (Smith et al., 2002).  
The common malignancy parameters in dog melanoma according to Smith et al., (2002) 
were the location (oral tumors were considered almost always malignant while cutaneous tumors 
were usually benign), mitotic index (especially for cutaneous and ocular melanoma), the nuclear 
atypia, invasion in upper epidermis, and necrosis. However, in the recent years, several studies 
indicated that the location alone should not be considered a malignancy criterion alone, because 
of a subset of oral and cutaneous melanocytic neoplasms proved a benign behavior (Milanta et 
al., 2002, Berghin et al., 2011). In our study all tumors, cutaneous tumors and those raised in 
mouth cavity, were diagnosed histological as malignant, only one tumor (11) had a benign 
histological, but deep invasion within the muscle fibers indicated it as malignant. However, it 
was a significant variation in malignancy degree among the samples in study. Many cutaneous 
melanomas showed clear signs of high malignancy, therefore, despite the fact that the cutaneous 
tumors have been considered usually benign, malignant tumors of the skin were not rare. 
In human pathology, the clinical significance of histological features was intensively 
investigated, but in canine tumors, relatively few clinical studies provide adequate description of 
the histological criteria used to diagnose a neoplasm as malignant (Smendly et al., 2011). In our 
study, the data about the clinical outcome were not available, this is why a correlation between 
growth fraction, survival rate and recurrence after surgery had not been made. The only possible 
correlation was done between different histological malignancy markers.  
There was no indication of significant difference in malignancy between the tumor cell 
types, this fact was confirmed by other previous study (Roels et al., 1999).  
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Unexpectedly, no correlation was found between growth fraction and other malignancy 
histological parameters like mitotic index, extension of necrosis or tumor infiltrating 
lymphocytes, in neither oral or cutaneous melanomas. Interestingly the mitotic index was 
positively correlated with extension of necrosis, both parameters being very important indicators 
of malignancy (Smith et al., 2002), but as far as we know this correlation was not made until 
now. Other data proved that Ki67+ nuclei percentage (reported to the surface occupied by all 
nuclei on the microscopical area) differed significantly between malignant and benign tumors, 
growth phase was also correlated to the survival time in Cox’s proportional hazards regression.  
This finding was available in both oral and cutaneous tumors (Roels et al., 1999). In oral 
tumors, the Ki67 immunolabeling was also correlated with survival. Growth phase, nuclear 
atypia, mitotic index were comparable predictive measures for the evaluation of canine 
melanoma (Berghin et al., 2011). The study establish even a threshold value of 19.5/HPF as limit 
between benign and malignant tumors. The tumors in study were all malignant, many of them 
highly aggressive, all of them were over the limit of 19.5 Ki+cells/HPF, and this might be why 
the findings of the present study could not confirm the literature data.  
Our study do not prove certain benefits of Ki67 immunolabeling as compared to classic 
histological parameters. However, the application of growth phase index in melanoma 
prognostication should not be excluded for “borderline” melanocytic tumors, correlated to other 
histological features and clinical stage.  
 
CONCLUSIONS 
 
In summary, we found that Melan A is highly specific marker, but it has a low sensitivity 
mainly in amelanotic tumors. Other melanocytic markers as Vimentin and S100 are less 
significant because of low specificity. In our tumor samples Ki67 (growth fraction) was not 
correlated to predominate cell type, mitotic index, tumor infiltrating lymphocytes or extension of 
necrosis, but mitotic index and necrosis showed a significant positive correlation.  
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